The medication is commonly used to provide symptomatic relief by addressing symptoms related to physical discomfort and systemic imbalance in infants and young children. The active ingredient is generally utilized for managing both pain and high temperature.

Dafalgan Bébé is applied across domains where additional symptomatic support is needed for managing symptoms associated with acute episodes, which includes elevated body temperature (fever) and acute mild to moderate pain conditions. Specifically, it is considered relevant for easing symptoms such as headache, earache (otalgia), throat pain, and generalized aches that may occur during common illnesses.

This medicine is commonly used during phases when symptoms become more noticeable in situations where patients experience distress linked to teething or the fever and pain following routine immunizations. This symptomatic assistance may help restore comfort and supports the patient during difficult episodes by easing distress caused by painful manifestations. It provides support that helps ease the overall symptom burden during periods of heightened symptoms.

---

Quick Fact: Relief for Fever and Pain

The primary benefit is in Antipyresis and Analgesia, and it may assist with reducing high temperatures and is applied in addressing the intensity of acute, short-term pain manifestations commonly seen in pediatric patients.

---

The official eligibility profile for Dafalgan Bébé (Paracetamol oral solution) is defined by government regulatory documents based on age, organ function, and specific clinical conditions.

Populations Absolutely Contraindicated

Use of this medicine is formally prohibited in the following groups:

• Infants less than two months of age.
• Patients with severe hepatic dysfunction or severe active liver disease.
• Individuals with a known hypersensitivity or allergy to paracetamol or any component of the formulation.
• Concurrent use with any other product containing paracetamol.

Populations Requiring Conditional Use or Caution

Use is restricted or requires professional caution for specific populations:

• Infants 2–3 months old: Use is conditional on meeting specific weight and gestation thresholds (over 4 kg, born after 37 weeks) and is limited to post-vaccination fever.
• Organ Function: Patients with severe renal impairment or non-cirrhotic alcoholic liver disease require caution due to increased toxicity hazards.
• Risk Factors: Individuals with chronic malnutrition, anorexia, or conditions causing glutathione depletion require restricted use.
• Pregnancy and Lactation: Use of the active ingredient is generally permitted if clinically necessary, provided it is administered at the lowest effective dose for the shortest possible duration. Available data do not contraindicate breastfeeding.

Interactions with other medicines and products

The interaction profile of Dafalgan Bébé (Acetaminophen) is structured around substances that modify its systemic exposure or alter existing pharmacodynamic effects, strictly based on regulatory documentation. Co-administration is formally restricted with any other product containing Paracetamol to prevent the critical risk of accidental overdose and subsequent severe hepatic injury.

Substances documented to affect the absorption and clearance include Probenecid, which reduces clearance and increases systemic exposure, and Cholestyramine, which reduces absorption. Due to this interference, regulators specify that the product must be administered at least one hour before or four hours after Cholestyramine. Conversely, drugs like Metoclopramide or Domperidone are documented to accelerate the speed of absorption.

In terms of drug interactions altering toxicity potential, certain Hepatic Enzyme Inducers, such as Carbamazepine and Phenytoin, may increase the formation of the toxic metabolite, elevating the risk of hepatotoxicity. Pharmacodynamic interactions involve Warfarin and other Vitamin K Antagonists, where prolonged regular use is officially stated to enhance the anticoagulant effect and increase the risk of bleeding.

Specific population notes exist for co-administration: The combination with Flucloxacillin carries an increased risk of High Anion Gap Metabolic Acidosis (HAGMA) in patients with severe renal impairment, sepsis, or malnutrition. Furthermore, the risk of liver damage is officially stated to be heightened with chronic excessive Alcohol use.

Dafalgan Bébé contains paracetamol (acetaminophen), which functions primarily as a central nervous system (CNS)-selective inhibitor. The molecule readily crosses the blood-brain barrier. Its mechanism involves the inhibition of cyclooxygenase (COX) enzymes, predominantly a central isoform or variant like COX-2 or the proposed COX-3, within the brain and spinal cord. This interaction reduces the enzymatic conversion of arachidonic acid to prostaglandin E2 ( PGE2) in the central compartment, particularly within the hypothalamus. Reduced central PGE2 concentration subsequently modulates the thermoregulatory set point, resulting in a systemic physiological consequence of decreased core body temperature.

Additionally, a bioactive metabolite, N-(4-hydroxyphenyl)arachidonoylamide (AM404), is formed in the CNS. This metabolite acts as an agonist at the transient receptor potential vanilloid-1 (TRPV1) channels and modulates components of the endocannabinoid system, including potential interaction with cannabinoid receptor type 1 ( CB1). This downstream molecular cascade enhances the descending inhibitory serotonergic pathways, leading to a system-level modulation of nociception.

Official Administration Protocol

The administration of Dafalgan Bébé, an oral solution containing Paracetamol (30 mg/ml), is governed by a strict weight-based dosing principle intended for children weighing 3 kg and above. The fundamental dosage requirement is 15 milligrams per kilogram of body weight for a single administration. To maintain consistent systemic drug levels, a minimum of 6 hours must be respected between each administration.

Dosing and Frequency Limits

The total intake is strictly limited, and the maximum total daily dose for a 24-hour period must not exceed 60 milligrams per kilogram. Treatment should be administered systematically to maintain consistency.

Specialized Administration Method

For accuracy, the solution must be measured using only the graduated dosing device supplied with the product. This device is specifically marked in kilograms (kg) to directly correlate the child’s weight to the precise volume required for the 15 mg/kg unit dose. The solution can be taken pure or may be mixed with a small amount of beverage or food, offering flexibility in intake.

Duration and Specific Adjustments

Use of the medication is intended to be as brief as possible, with a duration limit of 3 days for unsupervised use. Furthermore, the standard protocol mandates specific modifications for certain populations; for instance, the dosage must be reduced by half for infants with hepatic impairment or jaundice, ensuring the administration pattern accommodates physiological constraints.

Research Evidence / Overview of Studies for Dafalgan Bébé

Evidence for Use in Pain Relief (Analgesia)

Research has examined the use of the drug in children and infants who were experiencing outcomes related to physical discomfort. These were largely short-term randomized controlled trials (RCTs) and similar comparative trials, which was studied for its application in conditions characterized by fluctuating or episodic manifestations of mild to moderate pain. Researchers monitored outcomes such as patient-reported outcomes describing perceived discomfort or changes measured on pain scales, observing responses over defined time intervals. The findings describe patterns observed in the studies related to measured changes in pain outcomes in the observed pediatric populations during the study period. This research provides insight into short-term changes in symptom patterns.

Evidence for Use in Fever Reduction (Antipyresis)

Clinical trials have explored the drug’s use in conditions involving periods of heightened symptoms, specifically fever. These studies involved various comparative designs applied in research contexts involving fluctuating or unstable symptoms related to elevated body temperature. Researchers primarily examined outcomes related to systemic or functional imbalance, such as how changes in body temperature were monitored over short, defined timeframes. Studies report how symptoms evolved in the observed populations of children with fever, showing that the measured body temperatures data show patterns related to a shift over the observation period compared to the initial status. The research contributes to understanding symptom patterns in this context.

What is Still Uncertain and Requires Further Research

Despite the existing body of research, several aspects remain uncertain or unaddressed. Follow-up durations were limited in most research, meaning long-term outcomes are not well characterized. Comparative evidence is lacking for many alternative administration methods. Data for certain groups remain insufficient, particularly in premature infants or those with extremely low birth weights. Overall, subgroup findings are uncertain for specific ethnic or genetic populations, and research does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Key Studies & References Australasian Neonatal Medicines Formulary - Paracetamol Monograph (Informing use in specific pediatric age/weight groups)

Common questions about Dafalgan Bébé (FAQ)

---

Q: How quickly do people generally expect Dafalgan Bébé to start working?

Regulatory product information indicates that the active substance, paracetamol, generally begins to act for therapeutic purposes, such as pain relief or fever reduction, within one hour following oral administration.

---

Q: How long are the effects of Dafalgan Bébé generally understood to last?

The administration instructions provided in regulatory documents specify that a minimum time interval of four to six hours must be respected between doses. This interval is used to help manage the duration of the drug’s potential effects.

---

Q: Is Dafalgan Bébé considered an anti-inflammatory drug?

Official information states that the active substance is classified as a non-opioid analgesic (for pain relief) and an antipyretic (for fever reduction). It is not primarily considered an anti-inflammatory drug, as it is described as having little to no anti-inflammatory effect.

---

Q: Does Dafalgan Bébé contain sugar or sweeteners?

According to the official product information, the excipient list for the oral solution formulation includes components such as liquid sugar and saccharine sodium, which is a sweetener.

---

Q: What are the reasons why a child with kidney problems might not be able to use Dafalgan Bébé?

Regulatory documents indicate that the elimination of the active substance from the body may be delayed in individuals with impaired kidney function. For this reason, official guidance notes that a health professional's guidance is needed to determine appropriate use, such s adjusting the time interval between administrations.

---

Q: What is the maximum time period recommended for continuous use of Dafalgan Bébé?

The official advice provided in patient notices is not to administer the medicine for more than three days without seeking medical advice from a healthcare professional.

---

Q: Are there any warnings about Dafalgan Bébé and dehydration?

Official guidance indicates that caution is necessary and lists risk factors, including dehydration or conditions like severe hypovolemia (low fluid volume in the body), which are relevant for professional oversight.

---

Q: Is the information leaflet for Dafalgan Bébé available in multiple languages?

Official documents show that the Patient Information Leaflet (PIL) for some Dafalgan Pediatric product forms is documented to be available in multiple languages in certain regions, such as Dutch, French, and German.

---

Q: Why are there different concentrations of Dafalgan Bébé products?

Different concentrations and pharmaceutical formats are made available to allow for accurate dose adjustment based on the patient's weight. Weight-based dosing is a standard regulatory requirement for this active substance in children, and different strengths help ensure accuracy across various age and weight ranges.

---

Q: What ingredients are listed as inactive in Dafalgan Bébé liquid formulations?

The regulatory excipient list states that the inactive ingredients generally include components such as macrogol 6000, liquid sugar, glycerol, saccharine sodium, potassium sorbate (a preservative), citric acid, and flavorings.

---

Q: Can Dafalgan Bébé be used for fever after a vaccination?

Official public health guidance in some regions specifically addresses this use. The guidance recommends the use of infant paracetamol to help manage the risk of fever that may follow certain childhood vaccinations, such as the Meningococcal B (MenB) vaccine.

---

Q: Does Dafalgan Bébé have the same name in all countries?

While the core active ingredient, paracetamol, is consistent, the commercial name Dafalgan Bébé (or Pédiatrique) may vary by country. For example, in some regions, it is known by a different commercial name even though the active ingredient is identical.

---

Q: Are there any reports or studies regarding long-term use of the active ingredient in infants?

The research overviews included in regulatory summaries show that the existing body of clinical evidence is primarily based on short-term follow-up. Consequently, long-term outcomes and effects are described as not well characterized in the literature.

---

Q: Can Dafalgan Bébé be given to a child who is vomiting?

Regulatory documents for the active ingredient note that a different product form, such as a suppository, may be used for patients who are unable to take the medicine by mouth, such as those experiencing nausea or vomiting.

---

Q: Can Dafalgan Bébé be used at the same time as cold or flu combination medicines?

Official warnings formally restrict the medicine from being co-administered with any other product that contains Paracetamol (acetaminophen). This restriction applies to many common cold or flu combination medicines to prevent the risk of exceeding the total daily dose of the active substance.

---

Q: Are there different forms of Dafalgan Bébé (e.g., liquid, suppositories)?

The product is available in different pharmaceutical forms designed for pediatric use. These include the oral solution (liquid) for administration by mouth and suppositories for rectal administration.

---

Q: Are there any warnings about the product colorants or preservatives?

The patient leaflet contains a complete list of inactive ingredients (excipients), and specific warnings regarding certain components may be included based on regional regulatory requirements.

---

Q: Can Dafalgan Bébé be mixed with milk or formula?

Official administration instructions state that the oral solution is suitable to be taken pure or may be mixed with a small amount of any beverage or food.

---

Q: Does Dafalgan Bébé interact with any herbal supplements?

Regulatory documents note an interaction risk with certain Hepatic Enzyme Inducers. Some herbal supplements, such as St. John's Wort, have been described in regulatory contexts as having the potential to affect the way the body processes the active ingredient.

---

Q: What are the key pieces of information to tell a healthcare provider about Dafalgan Bébé use?

Official guidance emphasizes informing a health professional about any existing liver or kidney conditions, chronic malnutrition, and all other medicines being administered, including any other products containing Paracetamol, to ensure appropriate use.

---

Q: Are there warnings about administering Dafalgan Bébé rectally?

The oral solution product is specified by regulators for the oral route of administration. For rectal use, a separate suppository form is available and is designated specifically for that route of administration.

Storage and Disposal Instructions

The storage and disposal of Dafalgan Bébé (paracetamol oral solution) must comply strictly with regulatory labeling to maintain efficacy and ensure safety.

---

Storage Requirements

Condition	Regulatory Requirement
Temperature	Must be stored below 25°C; do not refrigerate or freeze the solution.
Protection	Keep in the original container and protected from light in a dry place.
Child Safety	Mandatory to store the medicine out of the sight and reach of children.
Stability	Do not use after the expiry date. The product must be discarded after 3 to 6 months following the first opening of the bottle (period varies by region).

---

Disposal Requirements

Official instructions prohibit discarding unused or expired product via wastewater or household waste. The medicine and its waste material must be disposed of in accordance with local requirements, typically by returning it to a pharmacist for environmentally safe disposal.